According to class M2.1 of the World Anti-Doping Agency's (WADA's) Prohibited List, the manipulation of doping control urine samples to alter their integrity and validity is prohibited both in-and out-of-competition. However, some paraplegic athletes with an overactive bladder need to be regularly treated with anti-cholinergic and anti-spasmodic drugs such as oxybutynin, which are often administered intravesically to reduce the substantial side effects observed after oral application. So far, it remains unclear whether such bladder instillations have a negative impact on analytical procedures and thus represent an anti-doping rule violation.
Introduction
Many patients with spinal cord injuries additionally suffer from a neurogenic bladder with urinary incontinence [1] . The underlying overactivity and hyper-reflexia of the bladder detrusor muscle are routinely treated with clean intermittent catheterization and anti-cholinergic drugs such as oxybutynin [1] [2] [3] [4] . This synthetic tertiary amine competitively binds to the M2 and M3 muscarinic receptors on the detrusor smooth muscle cells, thus inhibiting cholinergic transmission. Moreover, oxybutynin has a direct muscle-relaxant effect mediated through calcium channel blockade and acts as local anesthetic [2, 4] .
Following systemic administration, the non-selective binding of oxybutynin and its main metabolite N-desethyl-oxybutynin to M1, M2, and M3 muscarinic receptors in other tissues such as the parotid gland, the cerebral cortex, and the heart often results in undesirable effects including, for example, dryness of the mouth, dizziness, drowsiness, and palpitations [2, 3] . By contrast, intravesical instillations with oxybutynin were found to provide a comparable clinical efficacy with minimized anti-cholinergic side-effects due to circumvention of the hepatic first pass metabolism [2, 3] . Especially for patients already using clean intermittent catheterization, it represents a convenient treatment alternative [2] [3] [4] . Usually, up to 30 mL of a saline solution containing several milligrams of oxybutynin are instilled through the urethra by using an intravesical catheter and retained in the bladder until the next catherization/voiding of urine (Figure 1 ).
Also some paraplegic athletes have a neurogenic bladder and therefore perform regular intravesical oxybutynin instillations. However, according to the World Anti-Doping Agency's (WADA's) Prohibited List [5] , urine tampering including substitution and adulteration is prohibited both in-and out-of-competition. As the composition of urine can be significantly altered by intravesical instillations, this therapeutic strategy can potentially be considered as a violation of anti-doping rules. Hence, the aim of this pilot study was to investigate whether bladder instillations -conducted shortly before a doping control or on a regular basis -have a negative effect on the integrity and analysis of the collected urine samples. This article is protected by copyright. All rights reserved.
Material and methods

Sample collection
Six sets of urine samples were collected from five paraplegic athletes (three male athletes, two female athletes) before and after a therapeutic intravesical instillation with oxybutynin hydrochloride. For an intra-individual comparison, one subject delivered two sample sets (XD and XE, Table 1 ). As shown in Figure 2 , the participants were asked to collect 50-80 mL of the last urine catheterized prior to the bladder instillation (P0) as well as up to three samples after the treatment (P1-P3) according to their individual catheterization schedule. The oxybutynin hydrochloride concentration of the solution ranged from 0.025% to 0.1% and volumes between 7.5 ml and 20.0 mL were instilled, depending on the athletes' individual therapeutic regimen ( Table 1) . Following collection, urine samples were stored at 4°C and sent to the laboratory within 48 hours.
Sample analysis & data evaluation
All urine samples were tested for the presence of performance-enhancing drugs by using established analytical procedures [6] [7] [8] [9] and the concentrations and ratios of natural/endogenous steroids (contributing to the so-called steroid profile) were determined by GC-MS(/MS) and specific gravity-adjusted [9, 10] . pH-Value and specific gravity were measured by using a DMA 38 Density Meter (Anton Paar, Graz, Austria), a Consort C3010 Analyzer (Thermo Fisher Scientific, Waltham, MA), and a PS61 autosampler (MLE, Dresden, Germany). The presence of oxybutynin was qualitatively determined by GC-MS.
To investigate the direct effects of intravesical oxybutynin instillations on the detectability of doping agents, all samples (subjects XA-XF, samples P0-P3) were subsequently fortified with 25 model compounds representing different classes of doping agents (anabolic agents, cannabinoids, diuretics, glucocorticoids, hormone and metabolic modulators, and stimulants) at low and medium concentrations ( Table 2 ) and re-analyzed by means of routine doping control LC-MS and GC-MS methods.
The acquired data was evaluated with regard to the following aspects: with regard to the signal intensities or the presence of interferences)
Results and discussion
All samples were routinely tested for the presence of commonly monitored performanceenhancing drugs by using different GC-MS and LC-MS approaches. As shown in Table 2 , all samples were tested negative in the initial testing procedures. The pH and specific gravity values ranged from pH 5.4-7.3 and 1.004-1.025, respectively ( Table 1) , and no significant differences were observed between the samples collected before and after the bladder instillation. This also applies to the steroid profile data, which are summarized in Supporting Information Table 1 : Both before and following oxybutynin instillation, all markers [11] . The remaining markers and ratiosexcept for A/Twere below the respective thresholds and all other subsequent samples were found unsuspicious.
Oxybutynin was present in most of the urine specimens and as to be expected, the highest amounts were detected in the first samples (P1) collected 57-300 min after the intravesical instillation of the drug ( Table 1 ). In three sample sets (XD, XE, & XF), also the samples obtained before the oxybutynin treatment contained significant amounts of the drug, arguably remainders of prior treatments. Oxybutynin could not be detected in two samples collected before the bladder instillation (XA-P0 and XC-P0) as well as one of the last samples collected after the treatment (XD-P3). Here, the absence of oxybutynin can probably be attributed to the collection time after the last instillation (XA-P0: > 25 h; XB-P0: > 15 h; XD-P3: > 8 h).
Following initial testing, 25 model compounds were added to the urine specimens at two different concentration levels. Sample re-analysis demonstrated that neither the presence of oxybutynin nor the intravesically retained fluid had any significant impact on the detectability of the different model compounds ( Table 2) . No systematic intra-or inter-individual differences were observed. In a few samples, the exogenous anabolic androgenic steroids 18nor-oxandrolone and epi-/trenbolone could not be detected, especially when spiked at low concentrations (2 and 1 ng/mL) below the WADA minimum required performance level (MRPL) of 5 ng/mL [12] . In case of Epi-/Trenbolone, this phenomenon could be observed in samples collected both before and following oxybutynin treatment. Consequently, it was attributed to occasionally observed matrix effects. By contrast, NorOxandrolone could not be detected in a total of two samples -XB-P1 fortified at low and medium concentration (2 and 10 ng/mL) and XF-P1 fortified at low concentration (2 ng/mL). As NorOxandrolone was unambiguously detected in the other four samples (XA-P1, XC-P1, XD-P1, and XE-P1), it appears unlikely that the presence of oxybutynin was interfering with the detection of the drug.
But as it cannot be ruled out with absolute certainty, further studies with more participants should be conducted in the future.
In Figure 3 , the extracted ion chromatograms of the diuretic hydrochlorothiazide for an exemplary sample set (XD) are displayed. As expected, both the samples collected before and after the intravesical oxybutynin hydrochloride instillation were tested negative for hydrochlorothiazide. When the analyte was added to the samples, low (20 ng/mL) and medium (100 ng/mL) level concentrations of the diuretic were unambiguously detected. Altogether, these findings indicate that neither intravesical instillations conducted on a regular basis and shortly before a doping control, nor the concomitant use of oxybutynin hydrochloride do alter the integrity and validity of doping control urine samples.
Conclusions
Many paraplegic athletes suffer from a neurogenic bladder and are regularly treated with intravesical oxybutynin instillations. As urine tampering including substitution and adulteration is prohibited in sports, such a medical intervention can potentially be considered as sample manipulation and a violation of anti-doping rules. Within this pilot study, it could be demonstrated that intravesical instillations with oxybutynin hydrochloride did not affect routine tests for a total of 25 model substances, and the method of bladder instillation as such does not appear to require specific attention in the context of doping control procedures.
However, future studies should clarify whether this also applies to bladder irrigation procedures with antiseptics such as chlorhexidine [14] . This article is protected by copyright. All rights reserved. 
